Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Figs Inc (FIGS) Price & Performance

Cytokinetics IncTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Figs Inc — how do they compare? Cytokinetics Inc trades at $76.62 (market cap $10.63B), while Figs Inc trades at $14.48 (market cap $2.37B). The key difference: Cytokinetics Inc is far larger — about 4.5× Figs Inc's market cap. Which is the better fit depends on your goals.

CYTKFIGS
Market Cap
$10.63B$2.37B
Sector
TechnologyConsumer Cyclical
52-Week High
$87.26$17.12
52-Week Low
$34.31$6.57
Enterprise Value
$10.74B$2.13B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.

The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.

Figs Inc

FIGS stock trades at $14.39, up 0.91% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with 28.8% revenue growth, and raised its full-year outlook. Valuation remains elevated with a P/E of 43.24 and P/S of 3.83, while profitability improved with a net income margin of 8.72% in 2025.

The outlook is positive given accelerating revenue growth and margin expansion, but the rich valuation poses a risk if execution falters. Analyst consensus is bullish with a $19.50 price target, though high RSI readings suggest near-term overbought conditions. Key risks include second-half execution challenges and competitive pressures in healthcare apparel.

Returns comparison

Trailing returns across standard periods

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About Figs Inc

FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.

Read more on FIGS